Washington Uni secures USD 16.5m to expand DIAN-TU anti-tau Alzheimer's platform

The [Washington University](https://app.allsci.com/organization/ASC-OH-0000000001530-1.0-1764853177) neurology department in St. Louis has received a [USD 16.5 million NIA R01 renewal](https://reporter.nih.gov/project-details/11392866) to continue the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Tau Next Generation (NexGen) prevention trial, one of the most ambitious anti-tau intervention platforms in Alzheimer's disease research. The award, now in its fifth year, reflects sustained federal commitment to tau-targeting strategies at a time when the AD field is recalibrating following mixed results from anti-amyloid therapies. The DIAN-TU NexGen platform is testing three mechanistically distinct anti-tau approaches — a tau antibody targeting soluble spreading, a genetic treatment to reduce tau production, and a small-molecule aggregation inhibitor — in carriers of dominantly inherited AD (DIAD) mutations. The trial enrolls 216 mutation carriers across 37 sites in 13 countries, spanning both asymptomatic individuals and those with mild symptoms. Biomarker endpoints include next-generation tau PET imaging, diffusion basis spectrum imaging MRI, and cerebrospinal fluid measures of soluble tau species, neurodegeneration, and inflammation. The platform's design incorporates a pooled placebo arm and a common-close structure intended to maximize statistical efficiency in a rare population. The scientific rationale is straightforward: DIAD carriers offer a genetically defined, predictable disease course that allows biomarker-driven Phase II trials to generate mechanistic signal before committing to large Phase III cognitive endpoint studies. Positive biomarker results in this population could accelerate tau-targeting programs into late-stage development for the far larger sporadic AD population. [Randall J. Bateman](https://app.allsci.com/researcher/ASC-PR-0000043986234-1.0-1722656313), the lead investigator, has built DIAN-TU into a globally recognized trial infrastructure. The platform previously ran Phase III trials of solanezumab and gantenerumab in DIAD, results that informed broader anti-amyloid development. The NexGen tau work represents a strategic pivot toward tau and combination amyloid-tau approaches as the field seeks to build on amyloid-clearing therapies with complementary mechanisms. In the competitive landscape, tau-targeting programs from Eli Lilly, Biogen, and AC Immune are in various clinical stages, but few have access to the genetically homogeneous DIAD population that DIAN-TU offers as a mechanistic test bed. The platform's multinational infrastructure and pooled placebo design give it structural advantages for generating interpretable Phase II data efficiently. *** This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: [https://allsci.com/news/](https://allsci.com/news/) --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/anti-tau-alzheimers-disease-trial-washington)